Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
Preference Tiotropium Respimat Study in COPD
In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD.
- Trial name
- NCT01810692
- Testing
- Group1:Spiriva® Respimat®, Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®
- Where
- 15 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study of Relationship Between Changes in Inflammation, Lung Function, Symptoms and Medication Use in COPD Patients
The intention with the study is to have a better understanding of what happens to COPD patients' symptoms, lung function and markers of inflammation over 12 weeks.
- Trial name
- CORAL (NCT04168216)
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to…
- Trial name
- NCT00961038
- Testing
- Ciprofloxacin (PulmoSphere, BAYQ3939)
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b
Dynamic pulmonary hyperinflation (DH) and intrinsic positive end-expiratory pressure (PEEP) are well known problems in COPD patients with acute and chronic respiratory failure.
- Trial name
- ComfortCOPD (NCT02585752)
- Testing
- Noninvasive ventilation
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- ResMed
Moderate to Severe Chronic Obstructive Pulmonary Disease
A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long…
- Trial name
- NCT07839884
- Testing
- Tilrekimig
- Volunteers
- 1,360 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a 12-week chronic-dosing study to assess the efficacy and safety of BGF MDI compared to BFF MDI in subjects with moderate to very severe COPD.
- Trial name
- NCT03081247
- Testing
- BGF 320/14.4/9.6 µg MDI, BFF 320/9.6 µg
- Sponsor
- Pearl Therapeutics, Inc.
COPD
Study in Patients With COPD
The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
- Trial name
- NCT00215449
- Testing
- Formoterol Fumarate
- Where
- 68 sites in United States
- Volunteers
- 690 people
- Sponsor
- Dey
Pulmonary Disease, Chronic Obstructive
Tiotropium (Spiriva) Rehabilitation Study
The study was designed to determine whether tiotropium inhalation capsules, compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in…
- Trial name
- NCT00274521
- Testing
- Tiotropium
- Where
- 19 sites in United States
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic…
- Trial name
- NCT02722304
- Testing
- ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- Baxalta now part of Shire
Pulmonary Disease, Chronic Obstructive
Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
This observational study is designed to more specifically describe the burden of the disease and the use of healthcare resources of subjects with eosinophilic COPD that may be eligible in the future for a biologic treatment.
- Trial name
- NCT03436511
- Where
- 4 sites in Spain
- Volunteers
- 341 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
AZD9668 Relative Bioavailability
This clinical study will aid future formulation development and optimisation of AZD9668 tablets by evaluating possible effects of minor changes to the formulation and process on the rate and extent of absorption.
- Trial name
- NCT01035411
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Emphysema, Acute Respiratory Distress Syndrome
Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
A new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs.
- Conditions
- Emphysema, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00288964
- Testing
- Hattler Respiratory Assist Catheter
- Where
- United Kingdom
- Sponsor
- Alung Technologies
Pulmonary Disease, Chronic Obstructive
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00115492
- Testing
- Fluticasone Propionate/Salmeterol Combination Product, Salmeterol
- Where
- 110 sites in United States, Canada
- Volunteers
- 797 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Obstructive Pulmonary Disease
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
- Trial name
- ASCENT COPD (NCT01966107)
- Testing
- Aclidinium Bromide
- Where
- 468 sites in United States, Canada
- Volunteers
- 3,635 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064402
- Testing
- arformoterol tartrate inhalation solution, Salmeterol
- Where
- 65 sites in United States
- Volunteers
- 741 people
- Sponsor
- Sumitomo Pharma America, Inc.
Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.
- Conditions
- Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease, Part III (J-SD) - Healthy Japanese Participants
- Trial name
- NCT03096795
- Testing
- MEDI3506
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Respiratory Failure, Neuromuscular Disease
Ventilator Monitoring in Early Exacerbation Detection
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing)…
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01644162
- Testing
- iVAPS ventilation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- ResMed
Chronic Obstructive Pulmonary Disease (COPD)
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
The purpose of this study is to describe patients' clinical and self-reported outcomes of treatment with budesonide / glycopyrronium / formoterol Metered dose inhaler (BGF MDI) in Romania in real-life setting, up to 6 month of…
- Trial name
- COnCORD (NCT06368427)
- Testing
- budesonide / glycopyrronium / formoterol
- Where
- 16 sites in Romania
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Scintigraphy Study of PT010 in COPD Patients
This study is a single treatment period, single dose gamma scintigraphy study investigating the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF-MDI).
- Trial name
- RD708/34000 (NCT03906045)
- Testing
- BGF-MDI
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.